Mustafa Kemal Yeniay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mustafa Kemal Yeniay has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Oktay Bilgir
Department of Hematology, Izmir City Hospital, University of Health Sciences, Izmir 35535, Turkey
2 shared publications - Zehra Narlı Özdemir
Ankara City Hospital, Ankara, Turkey
2 shared publications - Ahmet Gürdal
Department of Cardiology, University of Health Sciences, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey
1 shared publication - Ali İhsan Gemici
Division of Hematology, Dokuz Eylül University Hospital, İzmir 35340, Türkiye
1 shared publication - Aslı Bozdemir
Division of Hematology, Pamukkale University Hospital, Denizli 20070, Türkiye
1 shared publication - Atakan Tekinalp
Division of Hematology, Necmettin Erbakan University Faculty of Medicine Hospital, Konya 42080, Türkiye
1 shared publication
Latest Publications
- 13 November 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (4) , 159-165
Association of FISH cytogenetic risk and baseline PET/CT findings with early treatment response and disease progression in patients with newly diagnosed multiple myeloma
Aims: To evaluate the association of fluorescence in situ hybridization (FISH)-defined cytogenetic risk and baseline positron emission tomography/computed tomography (PET/CT) findings with early treatment response and early disease progression in patients with newly diagnosed multiple myeloma (MM). Methods: Seventy patients with newly diagnosed MM were included in this retrospective study. Clinical characteristics, International Staging System (ISS) and Revised ISS (R-ISS) stage, lactate dehydrogenase (LDH) level, FISH-defined cytogenetic risk, and baseline PET/CT parameters, including the number of focal lesions, maximum standardized uptake value (SUV max), extramedullary disease, bone marrow involvement, and metabolic risk group, were recorded. Treatment responses after the second and fourth cycles were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory associations with PFS were assessed using Cox proportional hazards regression. Results: According to baseline PET/CT, 81.4% of patients were classified as having a metabolically high-risk disease. Compared with the metabolically low-risk group, patients in the metabolically high-risk group achieved significantly higher rates of very good partial response (VGPR) after the second cycle (49.1% vs. 15.4%, p=0.032) and ≥VGPR after the fourth cycle (64.9% vs. 23.1%, p=0.011). However, progression rates did not differ significantly between the two groups (p=0.675). Although response rates and progression frequency were numerically higher in the FISH high-risk group, these differences did not reach statistical significance. Kaplan–Meier analysis demonstrated longer PFS in female patients (p=0.001); ≥VGPR after the fourth cycle was not significantly associated with PFS (p=0.116). In the multivariable Cox model (13 PFS events), female sex remained significantly associated with PFS (HR=0.067, 95% CI 0.008–0.569, p=0.013), although the estimate was unstable because of the very limited number of events. The 1-year PFS and OS rates were 86% and 92%, respectively. Conclusion: In this exploratory cohort, the study-specific PET/CT metabolic risk classification was associated with deeper early treatment responses but not with short-term disease progression. FISH-defined cytogenetic risk was not significantly associated with early response or progression. Given the short follow-up duration, limited number of events, and lack of external validation of the metabolic risk classification, these findings should be considered preliminary and do not establish the independent prognostic value of PET/CT or FISH-defined risk.
- 13 November 2026
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 4 (4) , 159-165
Association of FISH cytogenetic risk and baseline PET/CT findings with early treatment response and disease progression in patients with newly diagnosed multiple myeloma
Aims: To evaluate the association of fluorescence in situ hybridization (FISH)-defined cytogenetic risk and baseline positron emission tomography/computed tomography (PET/CT) findings with early treatment response and early disease progression in patients with newly diagnosed multiple myeloma (MM). Methods: Seventy patients with newly diagnosed MM were included in this retrospective study. Clinical characteristics, International Staging System (ISS) and Revised ISS (R-ISS) stage, lactate dehydrogenase (LDH) level, FISH-defined cytogenetic risk, and baseline PET/CT parameters, including the number of focal lesions, maximum standardized uptake value (SUV max), extramedullary disease, bone marrow involvement, and metabolic risk group, were recorded. Treatment responses after the second and fourth cycles were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory associations with PFS were assessed using Cox proportional hazards regression. Results: According to baseline PET/CT, 81.4% of patients were classified as having a metabolically high-risk disease. Compared with the metabolically low-risk group, patients in the metabolically high-risk group achieved significantly higher rates of very good partial response (VGPR) after the second cycle (49.1% vs. 15.4%, p=0.032) and ≥VGPR after the fourth cycle (64.9% vs. 23.1%, p=0.011). However, progression rates did not differ significantly between the two groups (p=0.675). Although response rates and progression frequency were numerically higher in the FISH high-risk group, these differences did not reach statistical significance. Kaplan–Meier analysis demonstrated longer PFS in female patients (p=0.001); ≥VGPR after the fourth cycle was not significantly associated with PFS (p=0.116). In the multivariable Cox model (13 PFS events), female sex remained significantly associated with PFS (HR=0.067, 95% CI 0.008–0.569, p=0.013), although the estimate was unstable because of the very limited number of events. The 1-year PFS and OS rates were 86% and 92%, respectively. Conclusion: In this exploratory cohort, the study-specific PET/CT metabolic risk classification was associated with deeper early treatment responses but not with short-term disease progression. FISH-defined cytogenetic risk was not significantly associated with early response or progression. Given the short follow-up duration, limited number of events, and lack of external validation of the metabolic risk classification, these findings should be considered preliminary and do not establish the independent prognostic value of PET/CT or FISH-defined risk.
- 15 August 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
- 15 August 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
- Open Access
- 12 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6232
Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye
Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed/refractory multiple myeloma (RRMM). This study represents one of the first multicenter real-world evaluations of elranatamab in Türkiye. Methods: This multicenter retrospective study included 87 patients with relapsed/refractory multiple myeloma treated with elranatamab. Clinical characteristics, treatment responses, immune-mediated toxicities, infectious complications, and supportive care practices were assessed. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Multivariable analyses were performed to identify factors associated with treatment response and clinical outcomes. Results: At 3 months, ORR was 47.1% in the ITT population, 54.7% in the mITT population, and 83.7% among evaluable patients; corresponding 6-month ORRs were 31.0%, 42.2%, and 81.8%, respectively. The high proportion of patients without landmark response assessments primarily reflected insufficient follow-up, early death, or disease progression. Elevated LDH remained independently associated with lower response probability and inferior clinical outcomes. Cytokine release syndrome (CRS) occurred in 69% of patients, with grade ≥ 3 events in 5.7%, whereas immune effector cell-associated neurotoxicity syndrome (ICANS) was infrequent (4.6%) and no grade ≥ 3 events occurred. Grade ≥ 3 infections occurred in 39% of patients, including CMV events requiring antiviral treatment in 24.1%. No HBV reactivation occurred among patients receiving antiviral prophylaxis. Median PFS and OS were 8.1 and 10.6 months, respectively. Conclusions: Elranatamab demonstrated early clinical activity and a manageable safety profile in a heavily pretreated real-world RRMM population. Infectious complications, including CMV events, remained clinically relevant, emphasizing the importance of supportive care. Longer follow-up is needed to characterize long-term outcomes.
- 12 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6232
Open AccessElranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye
Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed/refractory multiple myeloma (RRMM). This study represents one of the first multicenter real-world evaluations of elranatamab in Türkiye. Methods: This multicenter retrospective study included 87 patients with relapsed/refractory multiple myeloma treated with elranatamab. Clinical characteristics, treatment responses, immune-mediated toxicities, infectious complications, and supportive care practices were assessed. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Multivariable analyses were performed to identify factors associated with treatment response and clinical outcomes. Results: At 3 months, ORR was 47.1% in the ITT population, 54.7% in the mITT population, and 83.7% among evaluable patients; corresponding 6-month ORRs were 31.0%, 42.2%, and 81.8%, respectively. The high proportion of patients without landmark response assessments primarily reflected insufficient follow-up, early death, or disease progression. Elevated LDH remained independently associated with lower response probability and inferior clinical outcomes. Cytokine release syndrome (CRS) occurred in 69% of patients, with grade ≥ 3 events in 5.7%, whereas immune effector cell-associated neurotoxicity syndrome (ICANS) was infrequent (4.6%) and no grade ≥ 3 events occurred. Grade ≥ 3 infections occurred in 39% of patients, including CMV events requiring antiviral treatment in 24.1%. No HBV reactivation occurred among patients receiving antiviral prophylaxis. Median PFS and OS were 8.1 and 10.6 months, respectively. Conclusions: Elranatamab demonstrated early clinical activity and a manageable safety profile in a heavily pretreated real-world RRMM population. Infectious complications, including CMV events, remained clinically relevant, emphasizing the importance of supportive care. Longer follow-up is needed to characterize long-term outcomes.
- 1 January 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (1) , 75-77
Spontaneous Intramuscular Hematoma due to Subcutaneous Enoxaparın
- 1 January 2019
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 20 (1) , 75-77
Spontaneous Intramuscular Hematoma due to Subcutaneous Enoxaparın